Evodiamine and rutaecarpine inhibit several inflammatory diseases, including gouty arthritis, colitis, and atherosclerosis, through suppressing NLRP3 inflammasome activation (Shen et al., 2019; Ding et al., 2020; Luo et al., 2020; Cheng et al., 2023). This evidence concerns the gene NLRP3 and colitis.